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INTRODUCTION
The various bacterial antibiotic resistance mecha-
nisms include alteration / modification of the target site, 
degradation of the antibiotic molecule and reduction of 
effective intracellular antibiotic concentration as a re-
sult of decreased permeability and energy–dependent 
(or active) efflux 10 . Resistance genes are either car-
ried on the chromosomes of wild–type bacteria or on 
elements of extachromosomal, sometimes extraneous 
origins, such a resistance plasmids and transposons 8 .
The most common mechanism by which bacteria 
are resistant to antibiotics is by producing enzymes that 
inactivate the drugs. The β–lactam antibiotics (penicil-
lins and cephalosporins) can be inactivated by enzymes 
known as β–lactamases. Hundreds of β–lactamases 
have been described; they can be both plasmid or chro-
mosomally encoded, and have varying degrees of ac-
tivity against the different β–lactam antibiotics. Many 
bacteria produce multiple β–lactamases. In response to 
the proliferation and spread of β–lactamases, the phar-
maceutical industry has developed some β–lactam an-
tibiotics that are more resistant to hydrolysis by these 
enzymes. In addition, some combination drugs have 
been produced which contain both a β–lactam antibi-
otic and a β–lactamase inhibitor; the inhibitor has high 
affinity for the β–lactamase enzyme, irreversibly binds 
to it, and thereby preserves the activity of the β–lactam 
antibiotic 7 . About one–tenth of isolates of Gram–neg-
ative pathogens seem to produce extended–spectrum 
beta–lactamases (ESBL) 1 .
Gram–negative bacteria pursue various molecular 
strategies for development of resistance to β–lactam 
antibiotics: (a) generation of extended–spectrum β–
lactamases (ESBL) due to extension of the spectrum 
of already widely disseminated plasmid–encoded β–
lactamases by amino acid substitution; (b) acquisition 
of genes encoding ESBL from environmental bacteria 
as, for instance the CTX–M–type β–lactamases from 
Kluyvera spp.; (c) high–level expression of chromo-





 genes due to modifications in regulatory genes, 
mutations of the β–lactamase promoter sequence as 
well as integration of insertion sequences containing 
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4an efficient promoter for intrinsic bla genes; (d) mobi-
lization of bla genes by incorporation in integrons and 
horizontal transfer into other Gram–negative species 
such as the transfer of the ampC gene from Citrobacter 
freundii to Klebsiella spp.; (e) dissemination of plas-
mid–mediated carbapenemases as KPC and metallo–β–
lactamases, e.g. VIM and IMP; (f) non–expression of 
porin genes and/or efflux pump–based antibiotic resis-
tance 17 . Pseudomonas aeruginosa exhibits resistance 
to a variety of penicillins and cephalosporins, mediated 
by an alteration in porin proteins that form channels in 
the cell membrane 7 . 
The best–studied members of these pumps are 
the MexAB–OprM system of Pseudomonas aerugi-
nosa that are known to efflux antibiotics, heavy met-
als, dyes, detergents, solvents, plus many other sub-
strates 18 . Drug efflux systems pump out a broad range 
of chemically and structurally unrelated compounds 
from bacteria in an energy–dependent manner, without 
drug alteration or degradation 16 . Although drug efflux 
pumps are found in Gram–negative and Gram–positive 
bacteria, efflux mediated resistance in Gram–negative 
bacteria is a more complex problem due to the molecu-
lar architecture of the cell envelope. As a consequence, 
drug resistance in many cases is attributable to synergy 
between reduced drug intake (mainly due to low outer 
membrane permeability) and active drug export (via 
efflux pumps) 12 .
The MexAB–OprM system of P. aeruginosa con-
tributes to the antimicrobial resistance of wild–type 
strains and has the broadest substrate range of all char-
acterized P. aeruginosa efflux pumps. Substrates of 
this pump include β–lactams, β–lactamase inhibitors, 
quinolones, macrolides, tetracyclines, chlorampheni-
col, novobiocin, sulfonamides, trimethoprim and thio-
lactomycin 9 . 
P. aeruginosa is a leading cause of nosocomial in-
fections in public health. Carbapenem are potent agents 
for the treatment of this pathogen. However, the preva-
lence of carbapenem resistance among these bacteria 
has been increasing worldwide, particularly those me-
diated by acquired metallo–ß–lactamase (MBLs) 14 . 
MBLs eclipse the clinical efficacy of several broad–
spectrum ß–lactam antibiotics and the existing ß–lac-
tamase inhibitors. Moreover, the genetic elements usu-
ally associated with MBLs genes, facilitate their fast 
and widespread dissemination. Additionally, infections 
attributable to MBL–producing bacteria have been as-
sociated with an increased morbility and mortality 15 .
P. aeruginosa is frequently isolated from canine 
otitis in this region. From 882 canine otitis swabs 222 
strains were isolated. This indicates that it was the 
responsible ethiologic agent in 25.2% of cases of this 
pathology. The resistance to aminoglucosides was al-
ways over 50% with a maximun of 82.6% to amikacin 
and 81.4% to gentamicin. Low resistence to piperacil-
lin (5.6%), fluoroquinolons (11.3%) and the polipeptide 
colistin (23%), resting the ultimate antibiotics to threat 
the infection. Similar susceptibility we obtained from 
P. aeruginosa isolated from another animal clinical 
samples such as nasal, bronchial, conjuntival, vaginal 
and piodermitis swabs. We did not know the resistant 
pattern of this bacteria from non–chlorinated water, 
obtained by perforation, of this region. So we analysed 
carbapenems, ceftazidime and aztreonam as phenotyp-
ical indicator substrates of β–lactamases 2 in the strains 
of both origin. 
MATERIAL AND METHODS
Thirty strains of P. aeruginosa (18 from pathologi-
cal clinical samples: 10 canine otitis, 3 ant–bear fecal 
swabs, 2 diarrhoeic suckling–pig faeces, 2 rabbit ab-
scess, 1 ovine purulent exudate and 12 from non–chlo-
rinated water) were studied for their susceptibility to 
antibiotics such as polimyxin (300 U), colistin (10 μg), 
piperacillin (100 μg), gentamicin (10 μg) and ciproflox-
acin (5 μg) using antibiotic–diffusion in agar Mueller–
Hinton by Kirby–Bauer antibiogram 11 . 
The strains were also analysed to determine pheno-
tipically the presence of MBL: monodiscs of ceftazi-
dime (30 μg), aztreonam (30 μg), imipenem (10 μg), 
Figure 1. Antibiogram of P. aeruginosa of canine oti-
tis (ExO884) susceptible to all antibiotics.
Figure 2. Antibiogram of P. aeruginosa of canine oti-
tis (ExO929) resistant to imipenem (Im = 21 mm) and 
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5meropenem (10 μg) and one of ethilendiaminotet-
raacetic (EDTA, 1 μmol) as MBL inhibitor, were used 
according the agar diffusion method 3, 11 . The test is 
positive when there is synergism between EDTA and 
carbapenem discs 2 .
RESULTS
Of 18 strains from animal clinical samples (Table 
1) 100% were susceptible to meropenem, aztreonam, 
piperacillin and ceftazidime, 15/18 (83.3%) to imipe-
nem, 14/18 (77.7%) to colistin and 12/18 (66.6%) to gen-
tamicin and ciprofloxacin. 
Of 12 strains from non–chlorinated water (Table 
1), 100% were susceptible to meropenem, piperacillin, 
and polimyxin, 11/12 (91.6%) to aztreonam and cefta-
zidime, 10/12 (83.3%) to imipenem and gentamicin and 
8/12 (66.6%) to ciprofloxacin. There was not synergism 
between EDTA and carbapenem discs (Figures 1, 2, 3 
and 4). The detail of seven strains found resistant to 
one ß–lactam antibiotic and the diameter average of the 
inhibition halos are in Tables 2 and 3 respectively. 
DISCUSSION
As the phenotypic screening was negative for de-
tecting MBLs producing isolates, the resistance to imi-
penem observed in four of them, is more likely due to a 
decrease in the expression of OprD, an outer membrane 
protein channel that acts as the passage for imipenem 
entry in P. aeruginosa 13 . Owing that MBLs do not ef-
ficiently hydrolyse aztreonam, its sensibility would be 
a good predictor of the enzyme presence in resistant 
bacteria to imipenem and meropenem 3 . This was not 
the case in this work, where all the strains susceptible 
to aztreonam were also sensitive to meropenem. 
Reduced of outer membrane permeability results 
in reduced antibiotic uptake, leading to low–level drug 
resistance. In the presence of drug efflux pumps, the 
Table 1. Percentage of sensibility of 30 strains of P. aeruginosa.
n origin Im Mer Azt Pip Cftz Coli Poli G Cipro
18 clinical samples 83.3 100 100 100 100 77.7 – 66.6 66.6
12 non–cholin. water 83.3 100 91.6 100 91.6 – 100 83.3 66.6
Im: Imipenem, Mer: Meropenem, Azt: Aztreonam, Pip: Piperacillin, Cftz: Ceftazidime, Coli: Colistin, Poli: Polimyxin,  
G: Gentamicin, Cipro: Ciprofloxacin.
Table 2. Detail of resistance of 7 strains of P. aerugi-
nosa to ß–lactam antibiotics.
ref. origin Im Mer Azt Cftz
Ex O 929 canine otitis R (21) S (30) S (25) S (20)
Ex O 934 canine otitis R (21) S (35) S (25) S (21)
As 153 ant–bear rectal R (11) S (30) S (24) S (20)
A 8 non chol.water S (23) S (36) S (25) R (17)
A 10 non chol.water S (22) S (30) R (10) S (25)
A 12 non chol.water R (19) S (30) S (24) S (25)
A 13 non chol.water R (21) S (35) S (25) S (22)
Im: Imipenem, Mer: Meropenem, Azt: Aztreonam, Cftz: 
Ceftazidime, S: sensible, R: resistant. In brakets: diameter 
of inhibition halos (mm).
Table 3. Diameter average of inhibition halos of P. ae-
ruginosa from clinical samples and water (mm).
n origin Im Mer Azt Cftz
18
clin.samples 25.2 34.3 29.1 24.9
ranks 11–40 27–50 21–45 18–40
12
non–ch.water 23.0 33.3 23.9 23.3
ranks 19–27 28–40 10–28 17–25
Im: Imipenem, Mer: Meropenem, Azt: Aztreonam, Cftz: 
Ceftazidime.
Figure 3. Antibiogram of P. aeruginosa of ant–bear 
rectal swab (AsI53) resistant to imipenem (Im= 11 
mm) and sensitive to other antibiotics. 
Figure 4. Antibiogram of P. aeruginosa of non– chlo-
rinated water (AI3) resistant to imipenem (Im= 21 
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6resistance is amplified multiplicatively by synergism 
between reduced uptake and active efflux. This effect 
has been shown in 12 isolates of P. aeruginosa, of ani-
mal origin 4 . The synergism of reduced uptake and ef-
flux is most evident in the multiplicative action of the 
outer membrane permeability barrier and active efflux, 
which results in high–level intrinsic and/or acquired re-
sistance in many clinically important Gram–negative 
bacteria 8 . This mechanism may be the responsible of 
the resistance found in the strains of this work.
In contrast with public health where approximately 
40% of P. aeruginosa isolates are resistant to ceftazi-
dime, imipenem or levofloxacin 1 , direct selective pres-
sure is the most probable culprit of increased resistance. 
The chances for horizontal transfer of resistance and 
even virulence genes are increased by merely putting 
together bacteria that do not often interact 19 . Carbap-
enem resistance in human clinical isolates of P. aerugi-
nosa has risen notably in recent years. This bacteria has 
different mechanisms of carbapenem resistance such 
as decreased levels of OprD or overexpression of the 
MexAB–OprM efflux system. Also the emergence of 
MBL–producing bacteria is becoming a severe thera-
peutic problem 20 .
The introduction of carbapenems in antimicro-
bial chemotherapy in humans resulted in emergence 
of carbapenem hydrolyzing β–lactamases (carbap-
enemases); first in P. aeruginosa and Acinetobacter 
spp., later in Enterobacteriaceae 5 . At present, various 
β–lactamases are widespread in nearly every Gram–
negative pathogenic species. Often, these enzymes are 
responsible for therapy failure because of mediating 
multidrug–resistance. A rigorous surveillance network 
to track the evolution and spread of resistance is also 
needed and would probably result in significant savings 
in healthcare 21 . 
P. aeruginosa, recognized as human opportunistic 
pathogen is increasingly responsible for lethal noso-
comial infections. Treatment options are dramatically 
declining worldwide. This species has emerged as a 
relevant animal pathogen too. This is a consequence of 
massive antibiotic use and the large versatile genome 
of this organism. The strains we have studied have 
demonstrated important resistance to aminoglucosides 
other than β–lactamases. We agree with some authors 6 
that antimicrobial profiling of P. aeruginosa animal 
isolates may contribute to a better understanding of the 
development and the epidemiology of P. aeruginosa 
multi–drug resistance in our densely populated bio-
sphere with increasing human–animal interactions.
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